1 Instituto Oncolόgico Dr Rosell, Quirón Dexeus University Hospital, Barcelona, Spain ; 2 Department of Medical Oncology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy ; 3 Division of Thoracic Oncology, European Institute of Oncology (IEO), Milan, Italy ; 4 Pangaea Biotech, Barcelona, Spain ; 5 Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain ; 6 Molecular Oncology Research (MORe) Foundation, Barcelona, Spain ; 7 Germans Trias i Pujol Health Sciences Institute and Hospital, Campus Can Ruti, Badalona, Barcelona, Spain.
Transl Lung Cancer Res. 2016 Feb;5(1):2-15. doi: 10.3978/j.issn.2218-6751.2016.01.02.
Although the incidence of small cell lung cancer (SCLC) has declined during the past 30 years, it remains a frustrating disease to research and treat. Numerous attempts to enhance the anti-tumor effects of traditional chemotherapy for SCLC have not been successful. For any tumor to become cancerous, various genetic mutations and biologic alterations must occur in the cell that, when combined, render it a malignant neoplasm. New and novel therapies based on understanding these mechanisms of transformation are needed. Herein we provide an in-depth view of some of the genomic alterations in SCLC that have emerged as potential targets for therapeutic intervention.
尽管小细胞肺癌 (SCLC) 的发病率在过去 30 年中有所下降,但它仍然是一种令人沮丧的疾病,难以研究和治疗。无数试图增强传统化疗治疗 SCLC 的抗肿瘤效果的尝试都没有成功。任何肿瘤要癌变,细胞内必须发生各种基因突变和生物学改变,这些改变结合在一起使它成为恶性肿瘤。需要基于对这些转化机制的理解,开发新的、新颖的治疗方法。在此,我们深入探讨了 SCLC 中一些已经出现的基因组改变,这些改变可能成为治疗干预的潜在靶点。